利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.027 秒)

    Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
    3.
    发明授权
    Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist 有权
    使用低分子量肝素与GP IIb / IIIa拮抗剂组合的血小板聚集抑制

    公开(公告)号：US06136794A

    公开(公告)日：2000-10-24

    申请号：US240429

    申请日：1999-01-29

    申请人： Jacquelynn J. Cook ,  Robert J. Gould ,  Frederic L. Sax

    发明人： Jacquelynn J. Cook ,  Robert J. Gould ,  Frederic L. Sax

    IPC分类号： A61K45/06 ,  A61K31/725

    CPC分类号： A61K31/727 ,  A61K45/06

    摘要： A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.

    摘要翻译： 一种用于抑制哺乳动物血小板聚集的方法，包括向哺乳动物施用安全和治疗有效量的GPIIb / IIIa受体拮抗剂或其药学上可接受的盐以及安全和治疗有效量的低分子量肝素。 一种用于抑制哺乳动物血小板聚集的方法，包括向哺乳动物施用安全和治疗有效量的（2-S-（正丁基磺酰基氨基）-3 [4-（哌啶-4-基）丁氧基苯基] - 丙酸或 其药学上可接受的盐和安全和治疗有效量的低分子量肝素。

    Anticoagulant test
    4.
    发明授权
    Anticoagulant test 失效
    抗凝血试验

    公开(公告)号：US06210904B1

    公开(公告)日：2001-04-03

    申请号：US09170858

    申请日：1998-10-13

    申请人： Bohumil Bednar ,  Daniel M. Bollag ,  Robert J. Gould

    发明人： Bohumil Bednar ,  Daniel M. Bollag ,  Robert J. Gould

    IPC分类号： G01N3353

    CPC分类号： C07K16/2848 ,  A61K38/00 ,  C07K2317/24 ,  G01N33/68 ,  G01N33/6893 ,  G01N2333/70557

    摘要： The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combining i) a plasma sample of the patient; ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; and iii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex, and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.

    摘要翻译： 本发明是一种用于诊断通过给予GP IIb / IIIa受体拮抗剂诱导的血小板减少症的患者的方法，所述方法包括组合患者的血浆样品; ii）识别诱导结合位点上形成的诱导结合位点的可检测单克隆抗体 GP IIb / IIIa受体与纤维蛋白原受体拮抗剂与GP IIb / IIIa受体结合后， 和ii）GP IIb / IIIa受体：GP IIb / III受体拮抗剂复合物，以及在血浆存在下确定可检测单克隆抗体与复合物的缔合。

    Compounds and methods for identifying activated platelets
    5.
    发明授权
    Compounds and methods for identifying activated platelets 失效
    用于鉴定活化血小板的化合物和方法

    公开(公告)号：US5646000A

    公开(公告)日：1997-07-08

    申请号：US315034

    申请日：1994-09-29

    申请人： Bohumil Bednar ,  Melissa Egbertson ,  Robert J. Gould ,  George D. Hartman ,  Jules A. Shafer

    发明人： Bohumil Bednar ,  Melissa Egbertson ,  Robert J. Gould ,  George D. Hartman ,  Jules A. Shafer

    IPC分类号： C07D401/06 ,  C07D405/14 ,  C07D491/22 ,  C07D495/04 ,  G01N33/569 ,  G01N33/80 ,  G01N33/86 ,  G01N33/567 ,  C07D401/14

    CPC分类号： C07D401/06 ,  C07D405/14 ,  C07D495/04 ,  G01N33/56966 ,  G01N33/80 ,  G01N33/86 ,  G01N2500/00 ,  Y10S436/80 ,  Y10S436/811

    摘要： The invention is directed to a series of novel compounds, and their pharmaceutically acceptable salts, of the formula ##STR1## wherein R is C.sub.0-6 alkyl substituted with R.sup.5 or a mono or polycyclic aromatic or heteroaromatic system comprised of 5 or 6-membered aromatic or heteroaromatic rings that are either unsubstituted or substituted with one or more of R.sup.1 and R.sup.2 ; R.sup.1 and R.sup.2 are independently C.sub.1-6 alkyl, carboxyl, hydroxyl, azido, nitro, amino, C.sub.1-6 alkylamino, C.sub.1-6 dialkylamino, arylamino, aryl C.sub.1-6 alkylamino, hydroxysulfonyl or arylazo; aryl is a phenyl or naphthyl ring which is unsubstituted or substituted with one or more of R.sup.3 and R.sup.4 ; R.sup.3 and R.sup.4 are independently C.sub.1-6 alkyl, azido, nitro, amino, C.sub.1-6 dialkylamino or hydroxysulfonyl; R.sup.5 is ##STR2## provided that when R is an unsubstituted monocyclic ring, the monocyclic ring is not phenyl or pyridyl. Such compounds are useful as fluorescent probes for identifying antiplatelet agents which selectively bind to activated platelets.

    摘要翻译： 本发明涉及一系列新颖的化合物及其药学上可接受的盐，其中R是被R 5取代的C 1-6烷基或由5或6元芳族的单或多环芳族或杂芳族体系 或未被取代或被一个或多个R 1和R 2取代的杂芳环; R 1和R 2独立地是C 1-6烷基，羧基，羟基，叠氮基，硝基，氨基，C 1-6烷基氨基，C 1-6二烷基氨基，芳基氨基，芳基C 1-6烷基氨基，羟基磺酰基或芳基偶氮; 芳基是未被取代或被一个或多个R 3和R 4取代的苯基或萘基环; R 3和R 4独立地为C 1-6烷基，叠氮基，硝基，氨基，C 1-6二烷基氨基或羟基磺酰基; R5是或，条件是当R是未取代的单环时，单环不是苯基或吡啶基。 这样的化合物可用作识别选择性结合活化血小板的抗血小板剂的荧光探针。

    Transgenic Rodents Selectively Expressing Human B1 Bradykinin Receptor Protein
    6.
    发明申请
    Transgenic Rodents Selectively Expressing Human B1 Bradykinin Receptor Protein 审中-公开
    转基因啮齿动物选择性表达人B1缓激肽受体蛋白

    公开(公告)号：US20090007283A1

    公开(公告)日：2009-01-01

    申请号：US10573926

    申请日：2004-10-04

    申请人： John W. Hess ,  Robert J. Gould ,  Douglas J. Pettibone ,  Thomas F. Vogt ,  Richard Z. Chen

    发明人： John W. Hess ,  Robert J. Gould ,  Douglas J. Pettibone ,  Thomas F. Vogt ,  Richard Z. Chen

    IPC分类号： A01K67/027

    CPC分类号： A01K67/0275 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  C07K14/705 ,  C12N15/8509

    摘要： Non-human transgenic animals, such as transgenic mice, are generated which incorporate the a non-native form of the bradykinin B1 receptor gene against a null phenotype for the native form of the bradykinin B1 receptor. An exemplified portion of the invention disclosed a transgenic mouse wherein a targeting construct containing a transgene encoding the human B1 bradykinin receptor gene is inserted downstream of and operatively linked to the native mice bradykinin B1 promoter. This targeting construct also contains a fluxed neomycin resistance gene. The resulting transgenic animals are “humanized” for the bradykinin B1 receptor and are effectively on a null background for native, functional B1 receptor activity. These animals may be crossed with a Cre-deleter strain to generate transgenic offspring which absent of the floxed marker gene. The transgenic animals described herein provide for a model to The transgenic mice of the present invention provide for an animal model enabling the analysis of compounds that are selective for the human B1 bradykinin receptor, relative to the rodent (e.g., rat or mouse) B1 bradykinin receptor.

    摘要翻译： 产生非人转基因动物，例如转基因小鼠，其掺入缓激肽B1受体基因的非天然形式针对天然形式的缓激肽B1受体的无效表型。 本发明的示例性部分公开了一种转基因小鼠，其中含有编码人B1缓激肽受体基因的转基因的靶向构建体插入天然小鼠缓激肽B1启动子的下游并与之有效连接。 该靶向构建体还含有一种助溶的新霉素抗性基因。 所得到的转基因动物对于缓激肽B1受体是“人源化的”，并且对于天然的功能性B1受体活性而言，其无效背景是有效的。 这些动物可以与Cre-去除菌株杂交以产生不含斑点标记基因的转基因后代。 本文所述的转基因动物提供了本发明的转基因小鼠相对于啮齿动物（例如大鼠或小鼠）B1缓激肽提供能够分析对人B1缓激肽受体有选择性的化合物的动物模型的模型 受体。

    Hybridomas and monoclonal antibodies for an anticoagulant test
    7.
    发明授权
    Hybridomas and monoclonal antibodies for an anticoagulant test 失效
    用于抗凝血试验的杂交瘤和单克隆抗体

    公开(公告)号：US06538112B2

    公开(公告)日：2003-03-25

    申请号：US09823444

    申请日：2001-03-30

    申请人： Bohumil Bednar ,  Daniel M. Bollag ,  Robert J. Gould

    发明人： Bohumil Bednar ,  Daniel M. Bollag ,  Robert J. Gould

    IPC分类号： C07K1600

    CPC分类号： C07K16/2848 ,  A61K38/00 ,  C07K2317/24 ,  G01N33/68 ,  G01N33/6893 ,  G01N2333/70557

    摘要： The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combining i) a plasma sample of the patient; ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; and iii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex, and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.

    摘要翻译： 本发明是一种用于诊断通过给予GP IIb / IIIa受体拮抗剂诱导的血小板减少症的患者的方法，所述方法包括组合患者的血浆样品; ii）识别诱导结合位点上形成的诱导结合位点的可检测单克隆抗体 GP IIb / IIIa受体与纤维蛋白原受体拮抗剂与GP IIb / IIIa受体结合后， 和ii）GP IIb / IIIa受体：GP IIb / III受体拮抗剂复合物，以及在血浆存在下确定可检测单克隆抗体与复合物的缔合。

    Combination therapy for reducing the risks associated with cardiovascular disease
    8.
    发明授权
    Combination therapy for reducing the risks associated with cardiovascular disease 失效
    联合治疗减少与心血管疾病相关的风险

    公开(公告)号：US06403571B2

    公开(公告)日：2002-06-11

    申请号：US09764511

    申请日：2001-01-18

    申请人： Robert J. Gould ,  Steven A. Nichtberger ,  Patricia A. Rhymer ,  Lars Olofsson

    发明人： Robert J. Gould ,  Steven A. Nichtberger ,  Patricia A. Rhymer ,  Lars Olofsson

    IPC分类号： A61K3152

    CPC分类号： A61K45/06

    摘要： The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.

    摘要翻译： 本发明涉及组合疗法和药物组合物，其包含治疗有效量的胆固醇降低剂如HMG-CoA还原酶抑制剂与可用于抑制血小板聚集的血小板聚集抑制剂的组合，用于抑制血栓形成 闭塞，并用于治疗，预防和降低心血管和脑血管事件发生的风险以及相关的血管闭塞障碍。

    Anticoagulant test
    9.
    发明授权
    Anticoagulant test 失效
    抗凝血试验

    公开(公告)号：US6063584A

    公开(公告)日：2000-05-16

    申请号：US975312

    申请日：1997-11-21

    申请人： Bohumil Bednar ,  Robert J. Gould

    发明人： Bohumil Bednar ,  Robert J. Gould

    IPC分类号： G01N33/566 ,  G01N33/86

    CPC分类号： G01N33/566 ,  G01N33/86

    摘要： The present invention is a method for identifying a patient at risk to developing fibrinogen receptor antagonist-induced thrombocytopenia which comprises incubating patient plasma with a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist complex to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex, incubating the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex with a secondary anti-human detectable antibody to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex, and detecting the presence of the secondary anti-human detectable antibody in the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex.

    摘要翻译： 本发明是用于鉴定处于发展纤维蛋白原受体拮抗剂诱发的血小板减少症的风险的患者的方法，其包括将患者血浆与GPIIb / IIIa受体：GPIIb / IIIa受体拮抗剂复合物孵育以形成GPIIb / IIIa受体：GPIIb / IIIa受体 拮抗剂：血浆抗体复合物，培养GPIIb / IIIa受体：GPIIb / IIIa受体拮抗剂：血浆抗体复合物与第二抗人可检测抗体形成GPIIb / IIIa受体：GPIIb / IIIa受体拮抗剂：血浆抗体： 人类可检测的抗体复合物，并检测GPIIb / IIIa受体中二级抗人可检测抗体的存在：GPIIb / IIIa受体拮抗剂：血浆抗体：第二抗人可检测抗体复合物。